Pomerantz Law Firm Launches Investigation into UroGen Pharma's Investor Claims

Investigation of UroGen Pharma Ltd. by Pomerantz Law Firm

Pomerantz LLP, a leading firm specialized in securities and class action litigation, has initiated an investigation regarding claims from investors of UroGen Pharma Ltd. (NASDAQ: URGN). The firm is particularly focused on allegations of potential securities fraud or other unlawful business practices involving the company's management. This investigation comes in light of a significant event impacting investor confidence in UroGen Pharma.

On May 16, 2025, the U.S. Food and Drug Administration (FDA) released a briefing document related to UroGen's drug UGN-102, designed for the treatment of bladder cancer. The document indicated concerns that arose from the Envision trial, which lacked a concurrent control arm. This shortcoming resulted in difficulties in interpreting the primary endpoints of the trial, such as the complete response and the duration of the response. In the briefing, the FDA reiterated its recommendation several times to UroGen for a randomized trial design to alleviate these concerns.

Following the FDA's disclosure, the company's stock price experienced a dramatic decline, plummeting by $2.54 per share, which marked a staggering 25.79% drop, closing at $7.31 per share on the same day. This event has prompted investors to seek legal counsel to determine whether the leadership of UroGen engaged in misconduct that may have misled them regarding the company's real performance and future prospects.

The scope of Pomerantz's investigation encompasses not only the handling of the trial's results but also the broader practices of the company's officers and directors. Investors who possess shares in UroGen are encouraged to connect with Pomerantz LLP for further insight into their rights and legal options. Danielle Peyton, a representative of the firm, can be contacted directly at [email protected] or through their New York office at 646-581-9980, ext. 7980.

Founded by Abraham L. Pomerantz, known as the forefather of class action law, Pomerantz LLP has a distinguished track record of advocating for victims of securities fraud. The firm has successfully recovered substantial settlements for numerous class members across various cases over the past 85 years.

This investigation underscores a growing concern among investors regarding transparency and accountability within UroGen Pharma. Following multiple calls from regulatory agencies for enhanced scrutiny, companies must operate with the utmost integrity, especially when the health and well-being of patients are at stake.

Investors with direct interests in UroGen are urged to stay informed as the situation unfolds. The evolving landscape not only pertains to UroGen's potential responses to these allegations but also highlights the broader implications for other pharmaceutical companies facing similar scrutiny.

For ongoing updates regarding Pomerantz's investigation or for further inquiries, stakeholders are encouraged to visit the firm's official website at www.pomlaw.com for more information on their initiatives and legal pursuits.